希罗达单药治疗老年晚期胃癌的临床观察  

Clinical Observation of Xeloda in Treatment of Elderly Patients with Advanced Gastric Cancer

作　　者：赵晓光[1] 宋明霞[1] 张艳珠[1] 

机构地区：[1]河南省焦作市人民医院,河南焦作454002

出　　处：《中国医学创新》2012年第20期41-42,共2页Medical Innovation of China

摘　　要：目的:观察希罗达单药治疗老年晚期胃癌的临床疗效及不良反应。方法:31例老年晚期胃癌患者,应用希罗达2500mg/(m2.d)口服,2次/d,第1～14天;21d为1个周期,至少完成2个周期后评价疗效和不良反应。结果:31例患者中CR0例(0%),PR9例(29%),SD7例(22.6%),PD15例(48.4%),总有效率29%;生活质量改善12例(38.7%),主要毒副反应为血液学毒性、消化道反应和手足综合征。结论:希罗达是治疗晚期胃癌安全、有效的药物,特别适宜于老年体弱的患者。Objective：To evaluate the efficacy and toxicity of Xeloda alone in treatment of elderly patients with advanced gastric cancer.Method：31 elderly patients with advanced gastric cancer received Xeloda orally at a dose of 2500 mg/m2,twice daily,on days 1-14,the cycles were repeated every 21 days,the evaluation of efficacy and toxicity were performed on all patients after 2 cycles at least.Result：Of the 31 patients,there were 0（0%） complete remission（CR）,9（29%）partial remission（PR）,7（22.6 %） stable disease（SD）.The total response rate was 29%.KPS improvement rate was 38.7%,the major toxicities were myelo suppression,gastrointestinal reaction and hand-foot syndrome.Conclusion：Xeloda is safe and effective in the treatment of advanced gastric cancer,especially for patients old and frail.

关 键 词：希罗达 晚期胃癌 疗效 

分 类 号：R735.2[医药卫生—肿瘤]